TPST 1495
Alternative Names: TPST-1495Latest Information Update: 22 Aug 2025
At a glance
- Originator Tempest Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Prostaglandin E EP2 receptor antagonists; Prostaglandin E EP4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Familial adenomatous polyposis
- No development reported Solid tumours
Most Recent Events
- 11 Aug 2025 Phase I trials in Familial adenomatous polyposis (PO)
- 28 Jul 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO)
- 28 Jul 2025 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in USA (PO)